Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.Explore and learn more about Conference Series : World's leading Event Organizer
As per available reports about 6 relevant journals, 5 Conferences, 3 workshops are presently dedicated exclusively to pre clinical avian influenza and about 2,070 articles are being published on pre clinical avian influenza.
A universal influenza virus vaccine that does not require frequent updates and/or annual immunizations will offer significant advantagesover current seasonal flu vaccines. The highly conserved influenza virus A M2 membrane protein has been previously suggested as apotential antigen target for such a vaccine. Here, we report systematic evaluation of M2 peptide conjugate vaccines (synthetic peptidesof M2 extracellular domain conjugated to keyhole limpet hemocyanin (KLH) or Neisseria meningitidis outer membrane protein complex(OMPC)) in mice, ferrets, and rhesus monkeys. The conjugate vaccines were highly immunogenic in all species tested and were able toconfer both protection against lethal challenge of either H1N1 or H3N1 virus in mice and reduce viral shedding in the lower respiratorytracts of mice and ferrets. The protection against lethal challenge in mice could also be achieved by passive transfer of monkey seracontaining high M2 antibody titers. In addition, we showed that M2 antisera were cross reactivewith M2 peptides derived from a widerange of human influenza A strains, but they failed to react with M2 peptides of the pathogenic H5N1 virus (A/Hong Kong/97).
OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.
The most promising compound, AV5080[(3R,4R,5S) 5-[(diaminomethylene)amino] 3-(1-ethylpropoxy) 4[(fluoroacetyl)amino]cyclohex-1-ene-1-carboxylic acid], is currently in pre-clinical development for treatment of influenza. This compound was stable in rat, dog and human plasma (>93% remaining after 24 h). AV5080 demonstrated picomolar activity against influenza neuraminidase in vitro, similar or better than Oseltamivir (the IC50 values of 0.03 nM and 0.07 nM against NA of A/duck/Minnesota/1525/1981, H5N1, and A/ Perth/265/2009, H1N1, 275H, respectively)
Socities :
• American Society for Microbiology
• Society for Applied Microbiology- UK
• International Union of Microbiological Societies
• Society for General Microbiology Journals
• American Society for Microbiology Career Connections
• The Canadian Society of Microbiologists
• European Microbiological Society.
• Illinois Society of Microbiology
• British Society for Microbial Technology
• New Zealand Microbological Society
Companies:
• Pfizer
• Novartis
• Roche
• Merck & Co.
• Sanofi
• GlaxoSmithKline
• Johnson & Johnson
• AstraZeneca
• Lilly
• AbbVie
This page will be updated regularly.
This page was last updated on November 5, 2024
